"UK MHRA (UK Medicines and Healthcare products Regulatory Agency) has since confirmed that general compliance with the principles and guidelines of Good Manufacturing Practice of the company's manufacturing unit at L-1, Chikalthana, Aurangabad," Wockhardt said in a filing to BSE
In view of this, the approval status of the said unit continues, it added.
"Further, UK MHRA has considered the said manufacturing unit suitable for risk based inspection with reduced inspection frequency of two years from the existing inspection frequency of 1 year," Wockhardt said.